Panacea Biotec Limited — Important, 12-11-2024: General Updates

Panacea Biotec Limited has made significant updates regarding its unlisted material subsidiary, Panacea Biotec Pharma Limited (PBPL). The board has appointed Mr. Rajesh Jain as a Non-executive Independent Director for a term of five years. This appointment brings in his extensive experience in governance, audit, and corporate finance, bolstering the subsidiary's leadership.

Additionally, PBPL is set to provide a corporate guarantee in connection with Panacea Biotec Limited's plan to raise up to US$ 20 million (approximately Rs. 168.16 Crore) through external commercial borrowings. This funding is aimed at expanding the manufacturing capacity for the hexavalent vaccine EasySix® and refinancing existing loans. The corporate guarantee is expected to facilitate these financial moves, providing a positive outlook for enhancing production capabilities and addressing financial obligations efficiently. Investors should watch closely for how these strategic decisions impact the overall growth trajectory of the company.